Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype

Cristina Missale, Flora Boroni, Sandra Sigala, Anna Zanellato, Roberto Dal Toso, Andrea Balsari, Pierfranco Spano

Research output: Contribution to journalArticle

Abstract

GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50% inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.

Original languageEnglish
Pages (from-to)290-298
Number of pages9
JournalEndocrinology
Volume135
Issue number1
DOIs
Publication statusPublished - Jul 1994

Fingerprint

Nerve Growth Factor
Phenotype
Cell Line
Somatotrophs
Nerve Growth Factor Receptors
Spiperone
Nerve Growth Factor Receptor
Nerve Growth Factors
Fluorescein
Hormones
Ligands
Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Missale, C., Boroni, F., Sigala, S., Zanellato, A., Dal Toso, R., Balsari, A., & Spano, P. (1994). Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology, 135(1), 290-298. https://doi.org/10.1210/en.135.1.290

Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. / Missale, Cristina; Boroni, Flora; Sigala, Sandra; Zanellato, Anna; Dal Toso, Roberto; Balsari, Andrea; Spano, Pierfranco.

In: Endocrinology, Vol. 135, No. 1, 07.1994, p. 290-298.

Research output: Contribution to journalArticle

Missale, C, Boroni, F, Sigala, S, Zanellato, A, Dal Toso, R, Balsari, A & Spano, P 1994, 'Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype', Endocrinology, vol. 135, no. 1, pp. 290-298. https://doi.org/10.1210/en.135.1.290
Missale, Cristina ; Boroni, Flora ; Sigala, Sandra ; Zanellato, Anna ; Dal Toso, Roberto ; Balsari, Andrea ; Spano, Pierfranco. / Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. In: Endocrinology. 1994 ; Vol. 135, No. 1. pp. 290-298.
@article{32039da8a39b4610aa92dc660f310f92,
title = "Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype",
abstract = "GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50{\%} inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.",
author = "Cristina Missale and Flora Boroni and Sandra Sigala and Anna Zanellato and {Dal Toso}, Roberto and Andrea Balsari and Pierfranco Spano",
year = "1994",
month = "7",
doi = "10.1210/en.135.1.290",
language = "English",
volume = "135",
pages = "290--298",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype

AU - Missale, Cristina

AU - Boroni, Flora

AU - Sigala, Sandra

AU - Zanellato, Anna

AU - Dal Toso, Roberto

AU - Balsari, Andrea

AU - Spano, Pierfranco

PY - 1994/7

Y1 - 1994/7

N2 - GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50% inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.

AB - GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50% inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0028200094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028200094&partnerID=8YFLogxK

U2 - 10.1210/en.135.1.290

DO - 10.1210/en.135.1.290

M3 - Article

C2 - 8013363

AN - SCOPUS:0028200094

VL - 135

SP - 290

EP - 298

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -